Monitoring pancreatic ductal adenocarcinoma (PDAC) remains a major challenge in oncology. Because the pancreas is located deep within the abdomen, imaging can be challenging for detecting early recurrence or subtle changes in tumor progression. Furthermore, the clinical "gold standard" biomarker, CA19-9, is notoriously unreliable — it is ...